Ghent University Academic Bibliography

Advanced

Targeting inflammation using selective glucocorticoid receptor modulators

Karolien De Bosscher UGent, Guy Haegeman UGent and Dirk Elewaut UGent (2010) CURRENT OPINION IN PHARMACOLOGY. 10(4). p.497-504
abstract
Glucocorticoids have been used since several decades in a variety of diseases in view of their potent anti-inflammatory properties. Nevertheless, the widespread use of glucocorticoids is hampered by the risk of side effects. Because the effects of glucocorticoids are mediated at large through interaction with the glucocorticoid receptor, which results in anti-inflammatory effects as well as side effects, much attention has been given to understanding the molecular regulation. Over the past decade, remarkable progress has been made in the mechanisms mediating glucocorticoid receptor dependent gene regulation. In this review we provide an overview of recent progress in understanding the mode of action of glucocorticoids and novel strategies to dissociate anti-inflammatory from metabolic side effects.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
keyword
GENE REPRESSION, PLANT-ORIGIN, RHEUMATOID-ARTHRITIS, CORTICOSTEROID-BINDING GLOBULIN, AZIRIDINE PRECURSOR, IN-VIVO, MOLECULAR-MECHANISMS, DNA-BINDING, KAPPA-B, LIGAND
journal title
CURRENT OPINION IN PHARMACOLOGY
Curr. opin. pharmacol.
volume
10
issue
4
pages
497 - 504
Web of Science type
Review
Web of Science id
000281138700019
JCR category
PHARMACOLOGY & PHARMACY
JCR impact factor
6.817 (2010)
JCR rank
11/249 (2010)
JCR quartile
1 (2010)
ISSN
1471-4892
DOI
10.1016/j.coph.2010.04.007
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1094948
handle
http://hdl.handle.net/1854/LU-1094948
date created
2011-01-06 11:23:56
date last changed
2011-01-10 14:31:15
@article{1094948,
  abstract     = {Glucocorticoids have been used since several decades in a variety of diseases in view of their potent anti-inflammatory properties. Nevertheless, the widespread use of glucocorticoids is hampered by the risk of side effects. Because the effects of glucocorticoids are mediated at large through interaction with the glucocorticoid receptor, which results in anti-inflammatory effects as well as side effects, much attention has been given to understanding the molecular regulation. Over the past decade, remarkable progress has been made in the mechanisms mediating glucocorticoid receptor dependent gene regulation. In this review we provide an overview of recent progress in understanding the mode of action of glucocorticoids and novel strategies to dissociate anti-inflammatory from metabolic side effects.},
  author       = {De Bosscher, Karolien and Haegeman, Guy and Elewaut, Dirk},
  issn         = {1471-4892},
  journal      = {CURRENT OPINION IN PHARMACOLOGY},
  keyword      = {GENE REPRESSION,PLANT-ORIGIN,RHEUMATOID-ARTHRITIS,CORTICOSTEROID-BINDING GLOBULIN,AZIRIDINE PRECURSOR,IN-VIVO,MOLECULAR-MECHANISMS,DNA-BINDING,KAPPA-B,LIGAND},
  language     = {eng},
  number       = {4},
  pages        = {497--504},
  title        = {Targeting inflammation using selective glucocorticoid receptor modulators},
  url          = {http://dx.doi.org/10.1016/j.coph.2010.04.007},
  volume       = {10},
  year         = {2010},
}

Chicago
De Bosscher, Karolien, Guy Haegeman, and Dirk Elewaut. 2010. “Targeting Inflammation Using Selective Glucocorticoid Receptor Modulators.” Current Opinion in Pharmacology 10 (4): 497–504.
APA
De Bosscher, K., Haegeman, G., & Elewaut, D. (2010). Targeting inflammation using selective glucocorticoid receptor modulators. CURRENT OPINION IN PHARMACOLOGY, 10(4), 497–504.
Vancouver
1.
De Bosscher K, Haegeman G, Elewaut D. Targeting inflammation using selective glucocorticoid receptor modulators. CURRENT OPINION IN PHARMACOLOGY. 2010;10(4):497–504.
MLA
De Bosscher, Karolien, Guy Haegeman, and Dirk Elewaut. “Targeting Inflammation Using Selective Glucocorticoid Receptor Modulators.” CURRENT OPINION IN PHARMACOLOGY 10.4 (2010): 497–504. Print.